Patient assessment in the diagnosis, prevention, and treatment of osteoporosis

Nutrition in Clinical Practice

Volumn 22, Issue 3, 2007, Pages 261-275

  Lata, Paul F ^a   Elliott, Mary E ^b,c  

^a Case Management Services ^*  (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBAMAZEPINE; COLECALCIFEROL; ELECTROLYTE; HEPARIN; HYDROCHLOROTHIAZIDE; MAGNESIUM; MEDROXYPROGESTERONE; PARATHYROID HORMONE; PHENOBARBITAL; PHENYTOIN; PHOSPHORUS; PREDNISONE; RETINOL; SERUM ALBUMIN; THIAZIDE DIURETIC AGENT; THYROTROPIN; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

ALBUMIN BLOOD LEVEL; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; AMENORRHEA; ANDROGEN DEPRIVATION THERAPY; ANOREXIA NERVOSA; BACKACHE; BLOOD CELL COUNT; BONE DENSITOMETRY; BONE DENSITY; BONE MASS; BONE RADIOGRAPHY; BONE TURNOVER; CALCIUM EXCRETION; CALCIUM INTAKE; CHRONIC KIDNEY DISEASE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIETARY INTAKE; DUAL ENERGY X RAY ABSORPTIOMETRY; ELECTROLYTE BLOOD LEVEL; ENTERITIS; FALL RISK; FALLING; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HISTORY OF MEDICINE; HUMAN; HYPERCALCIURIA; IDIOPATHIC HYPERCALCIURIA; JAW OSTEONECROSIS; LABORATORY TEST; LACTOSE INTOLERANCE; LIFESTYLE MODIFICATION; MAGNESIUM BLOOD LEVEL; NEPHROLITHIASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOMALACIA; PAGET BONE DISEASE; PARATHYROID HORMONE BLOOD LEVEL; PARKINSON DISEASE; PATIENT ASSESSMENT; PHOSPHATE BLOOD LEVEL; PHYSICAL ACTIVITY; PHYSICAL EXAMINATION; PROSTATE CANCER; QUALITY OF LIFE; RENAL OSTEODYSTROPHY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEASONAL VARIATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; ULTRASOUND; UROLITHIASIS; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; WRIST FRACTURE; AGED; CASE REPORT; DIFFERENTIAL DIAGNOSIS; FEMALE; FRACTURE; LIFESTYLE; METHODOLOGY; OSTEOPOROSIS; PREDICTION AND FORECASTING; RADIODENSITOMETRY; STANDARD;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DENSITOMETRY, X-RAY; DIAGNOSIS, DIFFERENTIAL; FEMALE; FRACTURES, BONE; HUMANS; LIFE STYLE; OSTEOPOROSIS; PREDICTIVE VALUE OF TESTS;

EID: 34347221585     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0115426507022003261     Document Type: Review

References (132)

1. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of the North American Menopause Society. Menopause. 2006;13:340-367.
2. Bernstein CM, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795-841.
3. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721-739.
4. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004;35:375-382. (Pubitemid 38953182)
5. Nevitt MC, Cummings SR, Kidd S, Black D. Risk factors for recurrent nonsyncopal falls: a prospective study. JAMA. 1989;261:2663-2668.
6. Melton LJ III, Crowson CS, Khosla S, Wilson DM, O'Fallon WM. Fracture risk among patients with urolithiasis: a population-based cohort study. Kidney Int. 1998;53:459-464.
7. Miller KK, Klibanski A. Amenorrheic bone loss. J Clin Endocrinol Metab. 1999;84:1775-1783.
8. van der Klift M, de Laet CE, McCloskey EV, et al. Risk factors for incident vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res. 2004;19:1172-1180. (Pubitemid 41110570)
9. Miller KK, Grinspoon SK, Ciampa J, Hier J, Herzog D, Klibanski A. Medical findings in outpatients with anorexia nervosa. Arch Intern Med. 2005;165:561-566.
10. Miller KK, Lee EE, Lawson EA, et al. Determinants of skeletal loss and recovery in anorexia nervosa. J Clin Endocrinol Metab. 2006;91:2931-2937.
11. Khan AA, Hanley DA, Bilezikian JP, et al. Standards for performing DXA in individuals with secondary causes of osteoporosis. J Clin Densitom. 2006;9:47-57.
12. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19:893-899. (Pubitemid 41103445)
13. Depo-Provera (medroxyprogesterone acetate injectable suspension) product monograph, Pfizer. Available at: http://www.depoprovera.com/pdf/pi.pdf. Accessed December 13, 2006.
14. Shahinain VB, Yong-Fang K, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-164.
15. Vestergaard P. Epilepsy, osteoporosis and fracture risk: a meta-analysis. Acta Neurol Scand. 2005;112:277-286.
16. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med. 1995;332:767-773.
17. Schulman S, Hellgren-Wangdahl M. Pregnancy, heparin and osteoporosis. Thromb Haemost. 2002;87:180-181.
18. Bauer DC, Ettinger B, Nevitt MC, Stone KL. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 2001;134:561-568.
19. Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998;351:1303-1307.
20. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167:188-194.
21. Yang X, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947-2953.
22. Kanis JA, Jonell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005;16:155-162.
23. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ. 1997;315:841-846.
24. Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int. 2005;16:737-742.
25. Cumming RG, Nevitt MC. Calcium for prevention of osteoporotic fractures in postmenopausal women. J Bone Miner Res. 1997;12:1321-1329.
26. Hallstrom H, Wolk A, Glynn A, Michaelsson K. Coffee, tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women. Osteoporos Int. 2006;17:1055-1064.
27. Lloyd T, Rollings N, Eggli DF, Kieselhorst K, Chinchilli VM. Dietary caffeine intake and bone status of postmenopausal women. Am J Clin Nutr. 1997;65:1826-1830.
28. Barrett-Connor E, Chang JC, Edelstein SL. Coffee-associated osteoporosis offset by daily milk consumption: the Rancho Bernardo Study. JAMA. 1994;271:280-283.
29. Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005;90:3215-3224.
30. Heaney RP. Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am J Clin Nutr. 2004;80(suppl): 1706S-1709S.
31. Penniston KL, Tanumihardjo SA. The acute and chronic toxic effects of vitamin A. Am J Clin Nutr. 2006;83:191-201.
32. Binkley N, Krueger D. Hypervitaminosis A and bone. Nutr Rev. 2000;58:138-144.
33. Office of Dietary Supplements, NIH Clinical Center, National Institutes of Health. Dietary supplement fact sheet: vitamin A and carotenoids. Available at: http://ods.od.nih.gov/factsheets/vitamina.asp. Accessed December 13, 2006.
34. Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA. 2002;287:47-54.
35. Opotowsky AR, Bilezekian JP. Serum vitamin A concentration and the risk of hip fracture among women 50 to 74 years old in the United States: a prospective analysis of the NHANES I follow-up study. Am J Med. 2004;117:169-174.
36. Michaelsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and risk of fracture. N Engl J Med. 2003;348:287-294.
37. Genaro Pde S, Martini LA. Vitamin A supplementation and risk of skeletal fracture. Nutr Rev. 2004;62:65-67.
38. Ballew C, Bowman BA, Sowell AL, Gillespie C. Serum retinol distributions in residents of the United States: Third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr. 2001;73:856-893.
39. Hamdy RC, Moore SW, Cancellaro VA, Harvill LM. Long-term effect of stroke on bone mass. Am J Phys Med Rehabil. 1995;74:351-356.
40. Kanis J, Oden A, Johnell O. Acute and long-term increase in fracture risk after hospitalization for stroke. Stroke. 2001;32:702-706.
41. Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone. 2004;35:1029-1037. (Pubitemid 39487348)
42. National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Belle Mead, NJ: Exerpta Medica; 1998.
43. Margolis KL, Ensrud KE, Schreiner PJ, Tabor HK. Body size and risk for clinical fractures on older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 2000;133:123-127.
44. Woo S, Hellstein JW, Kalmer JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-761.
45. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259.
46. Rubin SM, Cummings SR. Results of bone densitometry affect women's decisions about taking measures to prevent fractures. Ann Intern Med. 1992;116:990-995.
47. International Society for Clinical Densitometry 2005 Official Positions. Available at: http://www.iscd.org/Visitors/positions/OfficialPositionsText.cfm. Accessed December 13, 2006.
48. Cunningham J, Sprague SM, Cannata-Andia J, et al. Osteoporosis in chronic kidney disease. Am J Kidney Dis. 2004;43:556-571.
49. Masud T, Langley S, Wiltshire P, Doyle DV, Spector TD. Effect of spinal osteophytosis on bone mineral density measurements in vertebral osteoporosis. BMJ. 1993;307:172-173.
50. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res. 2000;15:183-187.
51. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
52. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C; Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Meta-analysis of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:570-578.
53. Berg AO, Allan JD, Frame PS, et al. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137:526-528.
54. Hodgson SF, Watts NB, Bilezikian JP, et al; AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003;9:545-564. Erratum in Endocr Pract. 2004;10:90.
55. Lichtenstein GR, Sands BE, Panzianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:797-813.
56. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu N. The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med. 2000;133:795-799.
57. van Hogezand RA, Banffer D, Zwinderman AH, McCloskey EV, Griffioen G, Hamdy NAT. Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease. Osteoporos Int. 2006;17:535-542.
58. Kemppainen T, Kroger H, Janatuinen E, et al. Bone recovery after a gluten-free diet: a 5-year follow-up study. Bone. 1999;55:355-360.
59. Coates PS, Fernstrom JD, Fernstrom MH, Schauer PR, Greenspan SL. Gastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass. J Clin Endocrinol Metab. 2004;89:1061-1065.
60. Bano G, Rodin DA, Pazianas M, Nussey SS. Reduced bone mineral density after surgical treatment for obesity. Int J Obes. 1999;23:361-365.
61. National Kidney Foundation. NKF K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Available at: http://www.kidney.org/professionals/kdoqi/guidelines-bone/index.htm. Accessed December 13, 2006.
62. Stehman-Breen C. Osteoporosis and chronic kidney disease. Semin Nephrol. 2004;24:78-81.
63. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in the incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586-1592.
64. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231-236.
65. Delmas PD, Zhengquing LI, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res. 2004;19:330-337.
66. Ettinger B, Black DM, Mitalk BH, et al. Reduction in vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637-645.
67. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction of the risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281-289.
68. US Preventive Services Task Force. Recommendations and rationale: screening for osteoporosis in postmenopausal women; 2002. Available at: http://www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm. Accessed December 13, 2006.
69. Health Care Financing Administration (HCFA). Medicare program: Medicare coverage of and payment for bone mass measurements: interim final rule with comment period. Fed Reg. 1998;63:34320-34328.
70. Gosfield E III, Bonner FJ Jr. Evaluating bone mineral density in osteoporosis. Am J Phys Med Rehabil. 2000;79:283-291.
71. Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs RW Jr, Lentle BC. Precision assessment and radiation safety for dualenergy X-ray absorptiometry (DXA): white paper of the International Society for Clinical Densitometry. J Clin Densitom. 2005;8:371-378.
72. Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Risk of fracture among women who lose bone density during treatment with alendronate: the Fracture Intervention Trial. Osteoporos Int. 2005;16:842-848.
73. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet. 1993;341:72-75.
74. Hans D, Dargent-Molina P, Schott A, et al. Ultrasonic heel measurements to predict hip fracture in elderly women: the EPIDOS Prospective Study. Lancet. 1996;348:511-514.
75. Siris ES, Brenneman SK, Barrett-Connor, et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int. 2006;17:565-574.
76. Nayak S, Olkin I, Liu H, et al. Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis. Ann Intern Med. 2006;144:832-841.
77. Schuit SCE, van der Klift M, Weel AEAM, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34:195-202. (Pubitemid 38142449)
78. McClung MR. Do current management strategies and guidelines adequately address fracture risk? Bone. 2006;38:S13-S17.
79. Vokes T, Bachman D, Balm S, et al. Vertebral fracture assessment: the 2005 ISCD official positions. J Clin Densitom. 2006;9(2 Suppl 2):37-46.
80. Lewiecki EM, Laster AJ. Clinical applications of vertebral assessment by dual-energy x-ray absorptiometry. J Clin Endocrinol Metab. 2006;91:4215-4222.
81. Greenspan SL, von Stetten E, Edmond SK, Jones L, Parker RA. Instant vertebral assessment: a noninvasive dual-x-ray absorptiometry technique to avoid misclassification and clinical management of osteoporosis. J Clin Densitom. 2001;4:373-380.
82. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY Study. J Bone Miner Res. 2000;15:1526-1536.
83. Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int. 2000;11:76-82.
84. Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res. 1998;13:1124-1133.
85. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J, for the Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int. 2000;11(suppl 6):2-17.
86. Bauer DC, Black DM, Garnero P, et al, for the Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial. J Bone Miner Res. 2004;19:1250-1258.
87. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction of fracture risk with risedronate. J Bone Miner Res. 2003;18:1051-1056.
88. Sarker S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002;17:1-10.
89. Bjarnason NH, Sarker S, Duong T, Mitalk B, Delmas PD, Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int. 2001;12:922-930.
90. Zerwekh JE, Ruml LA, Gottschalk F, Pak CYC. The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostatis in eleven normal subjects. J Bone Miner Res. 1998;13:1594-1601.
91. Hannon R, Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int. 2000;6(suppl):S30-S44. (Pubitemid 32039511)
92. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of c-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002;31:57-61.
93. Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87:4431-4437.
94. Jamal SA, Leiter RE, Bayoumi AM, Bauer DC, Cummings SR. Clinical utility of laboratory testing in women with osteoporosis. Osteoporos Int. 2005;16:534-540.
95. 3 in humans [abstract]. Endocrinology. 2004;145(suppl). Abstract OR22-2.
96. Bischoff-Ferrari H, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18-28.
97. Heaney RP. Vitamin D: how much do we need and how much is too much? Osteoporos Int. 2000;11:553-555.
98. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7:439-444.
99. Lips P, Duong T, Oleksik A, et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the Multiple Outcomes of Raloxifene Evaluation clinical trail. J Clin Endocrinol Metab. 2001;86:1212-1221.
100. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 2005;135:317-322.
101. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet. 1998;351:805-806.
102. Pasco JA, Henry MJ, Kotowicz MA, et al. Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study. J Bone Miner Res. 2004;19:752-758.
103. Valimaki VV, Alfthan H, Lehmuskallio E, et al. Vitamin D status as a determinant of peak bone mass in young Finnish men. J Clin Endocrinol Metab. 2004;89:76-80.
104. Elliott MB, Nolan NM. The role of vitamin D in the prevention and treatment of osteoporosis. Clin Rev Bone Miner Metab. 2004;2:373-388.
105. Binkley N, Krueger D, Cowgill CS, et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab. 2004;89:3152-3157.
106. Lensmeyer GL, Wiebe DA, Binkley N, Drezner MK. HPLC method for 25-hydroxyvitamin D measurement: comparison with contemporary assays. Clin Chem. 2006;52:1120-1126.
107. Hollis BW. Comparison of commercially available 125I-based RIA methods for the determination of circulating 25-hydroxyvitamin D. Clin Chem. 2000;46:1657-1661.
108. Giannini S, Nobile M, Carbonare LD, et al. Hypercalciuria is a common and important finding in postmenopausal women with osteoporosis. Eur J Endocrinol. 2003;149:209-213.
109. Favus MJ. Postmenopausal osteoporosis and the detection of so-called secondary causes of low bone density [editorial]. J Clin Endocrinol Metab. 2005;90:3800-3801.
110. Farrell R, Kelly CP. Celiac sprue. N Engl J Med. 2002;346:180-188.
111. Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002;50(suppl I):i1-i9.
112. Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk: a meta-analysis. Thyroid. 2003;13:585-593. (Pubitemid 36842665)
113. Uzzan B, Campos J, Cucherat P, Nony J, Boissel JP, Perret GY. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab. 1996;81:4278-4289.
114. Vestergaard P, Rejnmark L, Mosekilde L. Influence of hyperand hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int. 2005;77:137-144.
115. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-238.
116. Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA. 1995;273:808-812.
117. Francis RM. Androgen replacement in aging men. Calcif Tissue Int. 2001;69:235-238.
118. Synder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:1966-1972. (Pubitemid 30647018)
119. Lewiecki EM. Update on bone density testing. Curr Osteoporos Rep. 2005;3:136-142.
120. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137-1141.
121. El-Hajj Fuleihan G, Klerman EB, Brown EN, Choe Y, Brown EM, Czeisler CA. The parathyroid hormone circadian rhythm is truly endogenous: a general clinical research center study. J Clin Endocrinol Metab. 1997;82:281-286.
122. Carrol MF, Schade DS. A practical approach to hypercalcemia. Am Fam Physician. 2003;67:1959-1966.
123. Bilezikian JP, Potts JT, Fuleihan EG, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab. 2002;87:5353-5361.
124. Dickerson RN, Alexander KH, Minard G, et al. Accuracy of methods to estimate ionized and "corrected" serum calcium concentrations in critically ill multiple trauma patients receiving specialized nutrition support. JPEN J Parenter Enteral Nutr. 2004;28:133-141.
125. Ginty F. Dietary protein and bone health. Proc Nutr Soc. 2003;62:867-876.
126. Wagman RB, Maracus R. Beyond bone mineral density: navigating the laboratory assessment of patients with osteoporosis [editorial]. J Clin Endocrinol Metab. 2002;87:4429-4430.
127. Traub SL, ed. Basic Skills in Interpreting Laboratory Data. Bethesda, MD: American Society of Health-Systems Pharmacists; 1996.
128. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473-2483.
129. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab. 1983;56:1278-1281.
130. Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. J Clin Endocrinol Metab. 1977;45:1211-1219.
131. Zintzaras E, Germenis AE. Performance of antibodies against tissue transglutaminase for the diagnosis of celiac disease: a meta-analysis. Clin Vaccine Immunol. 2006;13:187-192.
132. Stenson WF, Newberry R, Lorenz R, Baldus C, Civitelli R. Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis. Arch Intern Med. 2005;165:393-399.